Prostate cancer is the most common non skin cancer in the United States.

Size: px
Start display at page:

Download "Prostate cancer is the most common non skin cancer in the United States."

Transcription

1 OPTIMIZING TREATMENT FOR ADVANCED PROSTATE CANCER Docetaxel and Thalidomide as a Treatment Option for Androgen- Independent, Nonmetastatic Prostate Cancer Gregory D. Leonard, MD, William L. Dahut, MD, James L. Gulley, MD, PhD, Philip M. Arlen, MD, William D. Figg, PharmD National Cancer Institute, Bethesda, MD Prostate cancer usually presents with early-stage disease, yet a significant proportion of patients present or will progress to androgen-independent, nonmetastatic prostate cancer (AIPC). Chemotherapy has demonstrated statistically significant improvements in palliation of AIPC. Docetaxel in particular has demonstrated high response rates as a single agent. Thalidomide is effective in treating many malignancies, including prostate cancer. Thalidomide may act synergistically with docetaxel through their antiangiogenic effects. We performed a phase II trial of docetaxel with or without thalidomide in patients with AIPC and demonstrated encouraging response rates with combination therapy. We advocate further investigation of this promising combination regimen. [Rev Urol. 2003;5(suppl 3):S65-S70] 2003 MedReviews, LLC Key words: Androgen-independent prostate cancer Docetaxel Thalidomide Palliative therapy Prostate cancer is the most common non skin cancer in the United States. In 2003, it is expected to account for 33% of new cancers among men; lung cancer is the second most common cancer among men, accounting for only 14%. 1 However, lung cancer is the most common cause of cancer death in men and is estimated to contribute to 31% of cancer deaths in 2003, with prostate cancer the second most common at 10%. It is anticipated that there will VOL. 5 SUPPL REVIEWS IN UROLOGY S65

2 Docetaxel and Thalidomide Combination Therapy continued be 220,900 new cases of prostate cancer and 28,900 deaths in The discrepancy between the incidence and mortality rates is due to the large proportion of prostate cancer that is diagnosed at an early stage and cured and to the relatively indolent natural history of the disease, which occurs largely in older men who often die of other conditions. Early diagnosis is likely due to screening, which contributed to the large increase in prostate cancer incidence in the late 1980s. Approximately 11% of black and 4% of white male patients present with metastatic disease and 10% 50% but one study analyzing 26 trials of cytotoxic chemotherapy given between 1987 and 1991 found an overall response rate of 8.7%. 3 These figures have improved with combination regimens, although responses are often defined by reductions in prostate specific antigen (PSA) levels and more accurate measures may be quality-of-life assessments and overall survival. Two chemotherapy trials have shown a significant benefit in symptom control in AIPC. The Canadian study randomized 161 patients with hormone refractory disease and pain to mitoxantrone (Novantrone, The development of hormone refractory or androgen-independent prostate cancer confers a poor prognosis, with a median survival of 9 to 12 months. Kalamazoo, MI) alternating with estramustine (Emcyt, Pharmacia and Upjohn, Kalamazoo, MI) and vinblastine (Velbe, Eli Lilly Australia, West Ryde, New South Wales). 6 Clinically stable or responding patients were then randomized to receive doxorubicin with or without strontium-89 (Metastron, Amersham Health Inc., Princeton, NJ). The median survival in patients treated with doxorubicin alone was 16.8 months but was 27.7 months for doxorubicin and strontium-89 (P =.0014). These trials offer promise for systemic therapy in AIPC and suggest an added benefit in outcomes by combining chemotherapy with other agents or therapies. One such combination is docetaxel and thalidomide. We will examine the rationale for the use of these agents in AIPC and present our experience with this combination. of early-stage cancers progress to metastatic disease. 1,2 Standard therapy is androgen ablation and often results in median survival of 2 3 years. 2 The development of hormone refractory or androgen-independent prostate cancer (AIPC) confers a poor prognosis with a median survival of 9 to 12 months. Bone-only disease is found in 60% of patients but can contribute to spinal cord compression or pathologic fractures in 30% of these patients. Systemic therapy options for AIPC are limited and palliative therapy is the primary goal. Chemotherapy has been studied extensively in AIPC, and while no prospective randomized phase III trial has demonstrated a survival benefit, results of two such trials are forthcoming. Comparison of chemotherapy regimens is often limited by variable definitions of response and difficulty in demonstrating response by radiologic techniques. Studies of single-agent chemotherapy have revealed response rates up to 30%, Serono, Inc., Geneva, Switzerland) and prednisone or prednisone alone. 4 Palliative response was found in 29% of patients on chemotherapy and 12% in the control arm (P =.01). The Cancer and Leukemia Group B 9182 study randomized 242 patients to mitoxantrone and hydrocortisone or hydrocortisone alone. 5 Pain symptoms were reduced in the combination arm. Other parameters in favor of chemotherapy were a PSA decline of > 75% (14% vs 7%) and improved time to progression (218 days vs 122 days; P =.005). Neither trial was able to demonstrate a statistically significant survival benefit to chemotherapy. Mitoxantrone and steroids have now become the reference regimen with which other therapies are compared in the treatment of AIPC. A phase II trial treated 103 AIPC patients with induction chemotherapy, composed of ketoconazole (Nizoral, Janssen Pharmaceutica Products, LP, Titusville, NJ) and doxorubicin (Adriamycin, Pharmacia and Upjohn, Docetaxel Docetaxel (Taxotere, Aventis Pharmaceuticals, Bridgewater, NJ) is a semisynthetic taxane. Its cytotoxic effects are mediated through two mechanisms. It binds to tubulin and induces stabilization of microtubules preventing microtubular depolymerization. This process inhibits mitosis resulting in the arrest of cells in the G2M phase of the cell cycle and results in apoptosis. Docetaxel may also cause phosphorylation and inactivation of bcl-2, which is found overexpressed in over 60% of AIPC biopsy specimens and leads to activation of the proapoptotic protein bax. Both of these mechanisms of action have been found to be more potent in docetaxel compared with paclitaxel. Docetaxel has shown activity in many solid tumors and has antiangiogenic effects in vitro. 7 It is the optimal regimen for platinum refractory non small cell lung cancer and is one of the few therapies to exhibit a survival advantage in metastatic breast S66 VOL. 5 SUPPL REVIEWS IN UROLOGY

3 Docetaxel and Thalidomide Combination Therapy cancer. Side effects include fluid retention, hypersensitivity reactions, gastrointestinal disturbance, skin and nail changes, and paresthesias. Figure 1. Mechanism of action of thalidomide. TNF-, tumor necrosis factor ; IL, interleukin. Inhibits angiogenesis Docetaxel in Prostate Cancer Clinical trials of single-agent docetaxel in AIPC have demonstrated response rates of 20% 60% (both PSA and measurable disease responses), which are superior to response rates with other single-agent chemotherapies in this disease. 8 These studies include docetaxel administration regimens of every 21 days and weekly. The weekly regimen has been shown to have a more favorable toxicity profile and is better tolerated in the elderly, which makes up most of the target population. 9 A number of trials have assessed the use of docetaxel in combination with estramustine. Estramustine was chosen because it also affects microtubular function and had shown synergy with other agents that effect tubulin, such as vinblastine. In the initial phase I trial, Petrylak and colleagues 10 treated 34 minimally pretreated or extensively pretreated patients with estramustine and escalating doses of docetaxel every 3 weeks. PSA responses of > 50% were seen in 63% of evaluable patients, and 28% of evaluable patients with bi-dimensionally measurable disease obtained a partial response. The overall survival at 1 year was 68%. Results from a phase II trial in 37 patients by the same investigator noted > 50% PSA responses and measurable disease partial responses in 68% and 55% of patients, respectively. 11 Similar results in other studies prompted the design of the Southwest Oncology Group Thalidomide Alters adhesion molecules trial. 12 This is a multicenter, randomized phase III study of docetaxel and estramustine versus mitoxantrone and prednisone in patients with hormone-refractory prostate cancer. Results from this trial are expected in Docetaxel has also shown encouraging results in combination with novel therapies such as Docetaxel has shown encouraging results in combination with novel therapies such as calcitriol, exisulind, and trastuzumab. calcitriol, exisulind (Aptosyn, Cell Pathways, Inc., Horsham PA), and trastuzumab (Herceptin, Genentech, Inc., South San Francisco, CA). Thalidomide Thalidomide ( -N{phthalimido} glutarimide [C 13 H 10 N 2 O 4 ]) is a synthetic glutamic acid derivative that was initially used as an over-the-counter sedative-hypnotic. It was used for pregnancy-associated morning sickness but caused teratogenicity and neuropathies and was taken off the market. 13 However, thalidomide was noted to have anti-inflammatory and immunomodulatory effects and was Direct Toxicity Inhibits TNF- IL-6 IL-10 IL-12 Increases IL-2 IL-4 IL-5 CD4+/CD8 Tumor Cell reintroduced to clinical practice by the Food and Drug Administration in 1998 for the treatment of erythema nodosum leprosum. To prevent further episodes of teratogenicity, the manufacturing company set up a program known as the System for Thalidomide Education and Prescribing Safety (STEPS). Thalidomide is now used in many diseases including Behçet s, Crohn s, discoid lupus, complex pain syndrome, and rheumatoid arthritis. The main side effects of thalidomide are constipation, sedation, and neuropathy; however, it has been well-tolerated at lower doses. The mechanism of action of thalidomide is poorly understood because it has the potential to work through many pathways (Figure 1). One such mechanism is antiangiogenesis as seen in animal corneal models. These antiangiogenic properties are mediated through metabolites of the parent compound and are likely due to inhibition of basic fibroblast growth factor and vascular endothelial growth factor. Thalidomide also inhibits tumor necrosis factoralpha (TNF- ) along with other cytokines and can alter adhesion molecules. The multiplicity of the VOL. 5 SUPPL REVIEWS IN UROLOGY S67

4 Docetaxel and Thalidomide Combination Therapy continued effects and efficacy of thalidomide in nonmalignant conditions stimulated interest in the antitumor activity of this compound. Thalidomide in Cancer Singhal and associates 14 gave escalating doses of oral thalidomide to 84 patients with refractory multiple myeloma who had received previous treatment. Serum or urine paraprotein levels were reduced by > 25% in 27 patients; of those 27 patients, 8 patients had a > 90% reduction in serum or urine paraprotein levels. Kaplan-Meir estimates of the mean overall survival after 12 months of follow-up was 58%. The efficacy of thalidomide was attributed to a direct effect on myeloma cells, antiangiogenesis, and the other properties previously described. However, microvascular density in bone marrow did not change in patients with a paraprotein response. Other studies have confirmed the beneficial effects of thalidomide in myeloma. Thalidomide has also shown activity in solid tumors. Most of the responses seen have been in Kaposi sarcoma although responses have also been documented in melanoma, brain, colorectal, hepatocellular, and renal cancers. Thalidomide and Prostate Cancer Microvessel density (MVD) has been reported to be higher in prostate cancer tissue than in adjacent hyperplastic or benign tissue. 15 Preclinical evidence also suggests that angiogenesis may play a key role in the development of aggressive prostate cancer lesions. 16 Clinical studies have observed a correlation between increased angiogenesis in primary tumor specimens and the future development of metastatic disease. The apparent importance of angiogenesis in the evolution of prostate cancer provides a rationale for the investigation of antiangiogenesis SUV max = 5.4 Metabolic Volume = 18.1 cm 3 CT Volume = 16.4 cm 3 PSA = 41 ng/ml SUV max = 3.4 FDG Study: 68-year-old man with AIPC Metabolic Volume = 6.0 cm 3 CT Volume = 13.5 cm 3 PSA = 28 ng/ml Pre-treatment Post-treatment Figure 2. Correlation of prostate specific antigen (PSA) decline with resolution of bone metastasis on positron emission tomography (PET) in a 68-year-old man after treatment with thalidomide for androgen-independent prostate carcinoma (AIPC). SUV max, maximum standard uptake value; CT, computed tomography. Figure 3. Correlation of prostate specific antigen (PSA) decline with resolution of bone metastasis on positron emission tomography (PET) in a 73-year-old- man after treatment with thalidomide for androgen-independent prostate carcinoma (AIPC). SUV max, maximum standard uptake value; CT, computed tomography. FDG Study: 73-year-old man with AIPC SUV max = 7.1 Metabolic Volume = 45 cm 3 CT Volume = 81 cm 3 PSA = 79 ng/ml SUV max = 3.4 Metabolic Volume = 71 cm 3 CT Volume = 154 cm 3 PSA = 34 ng/ml S68 VOL. 5 SUPPL REVIEWS IN UROLOGY

5 Docetaxel and Thalidomide Combination Therapy agents in AIPC. Figg and colleagues 17 previously reported our data on the use of thalidomide in 63 patients with AIPC. Thalidomide was administered in doses ranging between 200 mg and 1200 mg. This therapy resulted in a > 40% fall in PSA levels in 27% of patients and improvement in clinical symptoms in all responding patients. PSA declines often resulted in striking reductions in measurable disease on positron emission tomographic scan (Figures 2 and 3). No responses were seen in patients receiving high doses of thalidomide, and there was no correlation between MVD in the primary tumor and response to therapy. These encouraging results confirm the benefit of thalidomide in solid tumors and particularly AIPC. Docetaxel and Thalidomide in Prostate Cancer Single-agent docetaxel appears to be a promising chemotherapeutic agent in AIPC and may have improved efficacy in combination with other therapies. Thalidomide has also demonstrated efficacy in AIPC. A combination of docetaxel and thalidomide may be a reasonable therapeutic approach. To answer this question, we performed a randomized phase II trial on 75 patients with AIPC. Patients were treated with intravenous docetaxel (30 mg/m 2 for 3 of 4 weeks) with or without evening doses of oral thalidomide (200 mg/d) and both arms of the study had similar patient and tumor characteristics. A > 50% fall in PSA was found in 50% of patients in the combination arm and in 37% treated with docetaxel alone. Although this study was not powered to detect a statistically significant difference in survival, the median overall survival was doubled from 14.7 months in the docetaxel-alone arm to 28.9 months in the combination arm (P =.11). As anticipated, the addition of thalidomide to docetaxel contributed to an increase in some gastrointestinal and neurologic symptoms but overall the combination was well tolerated. The incidence of depression increased in the thalidomide containing arm of the study (10% vs 4%). Patients with a history of depression must be monitored closely. In our study, one patient committed suicide although he had no previous psychiatric history and A > 50% fall in PSA was found in 50% of patients in the combination arm and in 37% treated with docetaxel alone. died within 30 days of stopping thalidomide for progressive disease. Also of concern was the development of venous thromboembolism in 9 patients and transient ischemic attack or stroke in 3 of the first 43 patients treated with thalidomide and docetaxel, with no thromboembolic events in patients on docetaxel alone. In light of these findings, we treated subsequent patients enrolled to the combination arm with lowmolecular-weight heparin and no further episodes of thromboembolism were reported. Prostate cancer, like all cancers, is prothrombotic but overall is associated with a low inci- Main Points Clinical trials of single-agent docetaxel in androgen-independent prostate cancer (AIPC) have demonstrated response rates of 20% 60%, which are superior to response rates with other single-agent chemotherapies used in this disease. Docetaxel plus estramustine has been assessed in a number of trials. Estramustine was chosen because it, like docetaxel, affects microtubular function and has shown synergy with other agents that effect tubulin, such as vinblastine. After being removed from the market, thalidomide was reintroduced by the Food and Drug Administration in Thalidomide has anti-inflammatory and immunomodulatory effects and is used for the treatment of such diseases as Behçet s, Crohn s, discoid lupus, complex pain syndrome, and rheumatoid arthritis. A correlation between increased angiogenesis in primary tumor specimens and the future development of metastatic disease has been observed in clinical trials. The apparent importance of angiogenesis in the evolution of prostate cancer provides a rationale for the investigation of antiangiogenesis agents in AIPC. Docetaxel is a promising treatment for AIPC, and it has improved efficacy when combined with other therapies. Thalidomide has also demonstrated efficacy in AIPC, and so a combination of docetaxel and thalidomide may be a reasonable therapeutic approach. When given alone, thalidomide and docetaxel are associated with a low risk for thrombosis; in combination, however, venous thromboembolism (VTE) becomes a concern. Low-molecular-weight heparin was given to reduce the risk of VTE in patients receiving combination therapy with docetaxel and thalidomide. VOL. 5 SUPPL REVIEWS IN UROLOGY S69

6 Docetaxel and Thalidomide Combination Therapy continued dence of deep venous thrombosis or pulmonary embolism. Similarly, thalidomide and docetaxel as single agents are associated with a low risk for thrombosis. However, a number of studies using thalidomide have reported an increased incidence of thromboembolism in myeloma and one study reported it in renal cell carcinoma. Chemotherapy agents that have a predilection for endothelial damage, such as anthracyclines or taxanes, may exaggerate the prothrombotic effects of thalidomide. Summary Our trial of combined docetaxel and thalidomide compared with docetaxel alone in pretreated AIPC patients revealed significant benefits for the combination arm. This combination regimen compares favorably with other data on systemic therapy for AIPC. PSA and tumor responses were similar to previous trials and the survival advantage for combination therapy was encouraging. The regimen was relatively well tolerated although prophylactic anticoagulation is recommended to prevent thrombotic complications. Cardiotoxicity can be a significant complication with mitoxantrone and steroids but was rarely seen with docetaxel and thalidomide. A trial dedicated to analyzing endpoints such as overall survival and quality of life is warranted to determine the true significance of our findings. Conclusion Prostate cancer is the most common male cancer and the second most common cause of cancer death among men. Most men who die of prostate cancer have AIPC yet there are no prospective, randomized, phase III data of any therapy reporting a survival advantage with this stage of disease. Chemotherapy, however, has demonstrated improvements in symptom control, and at present, a combination of mitoxantrone and steroids is considered the standard of care for patients who are healthy enough for chemotherapy. Docetaxel has proved successful as a single agent in the treatment of AIPC. It has improved response rates in combination with estramustine and is currently under investigation combined with many novel agents. Thalidomide is frequently used for nonmalignant conditions and was shown to be of benefit in prostate cancer. Both docetaxel and thalidomide have antiangiogenesis properties and may be synergistic although their exact antitumor activity is likely multifactorial. Our experience with the combination of docetaxel and thalidomide in the treatment of patients with AIPC is promising. We have demonstrated response rates with this combination that compare favorably to historical results with either thalidomide or docetaxel alone. A doubling of the overall survival with the addition of thalidomide to docetaxel, although not statistically significant, is also encouraging. Caution must also be exercised in the use of this combination regimen as venous thromboembolism and depression may be increased. We advocate anticoagulation therapy and close supervision of all patients treated with the docetaxel and thalidomide combination. Our data warrants further investigation to determine whether this efficacious and relatively well-tolerated regimen can offer improvements in outcome to patients with AIPC. Larger trials with adequate power may detect a significant improvement in survival and will provide more data on toxicity and quality-of-life indexes. Alternative options to the present therapy of AIPC are welcome and would provide palliation and perhaps improved survival to a large population of the cancer community. References 1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, CA Cancer J Clin. 2003;53: Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol. 1999;26: Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71(3 suppl): Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol. 1996;14: Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17: Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357: Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61: Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Huntingt). 2002;16(6 suppl 6): Scholtz MC, Guess B, Barrious F, et al. Low-dose, single-agent weekly docetaxel is effective and well tolerated in elderly men with prostate cancer. Proc Am Soc C. 2001;20:173b (abstract 2441). 10. Petrylak DP, Macarthur RB, O Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17: Petrylak, DP. Docetaxel (Taxotere) in hormonerefractory prostate cancer. Semin Oncol. 2000; 27(2 suppl 3): Hussain M, Petrylak D, Fisher E, et al. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study Semin Oncol. 1999;26(5 suppl 17): Melin GW, Katzenstein M. The saga of thalidomide (concluded): Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med. 1962;267: Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341: Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer. 1995;75: Weidner N, Carroll P, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143: Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients wth androgen-independent prostate cancer. Clin Cancer Res. 2001; 7: S70 VOL. 5 SUPPL REVIEWS IN UROLOGY

Recent Progress in Management of Advanced Prostate Cancer

Recent Progress in Management of Advanced Prostate Cancer Review Article [1] April 15, 2005 By Philip W. Kantoff, MD [2] Androgen-deprivation therapy, usually with combined androgen blockade, is standard initial treatment for advanced prostate cancer. With failure

More information

New Hope for Patients with Metastatic Hormone-Refractory Prostate Cancer

New Hope for Patients with Metastatic Hormone-Refractory Prostate Cancer european urology supplements 5 (2006) 817 823 available at www.sciencedirect.com journal homepage: www.europeanurology.com New Hope for Patients with Metastatic Hormone-Refractory Prostate Cancer Ronald

More information

NCCP Chemotherapy Protocol

NCCP Chemotherapy Protocol Docetaxel Monotherapy 50mg/m 2 INDICATIONS FOR USE: INDICATION In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer

More information

Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone- Resistant Metastatic Prostate Cancer

Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone- Resistant Metastatic Prostate Cancer Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone- Resistant Metastatic Prostate Cancer Hamid Rezvani, Shirin Haghighi, Mojtaba Ghadyani, Hamid Attarian UROLOGICAL ONCOLOGY Taleghani

More information

TRANSPARENCY COMMITTEE OPINION. 15 February 2006

TRANSPARENCY COMMITTEE OPINION. 15 February 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial

More information

Weekly Administration of Docetaxel in Patients with Hormonerefractory Prostate Cancer: a Pilot Study on Japanese Patients

Weekly Administration of Docetaxel in Patients with Hormonerefractory Prostate Cancer: a Pilot Study on Japanese Patients Jpn J Clin Oncol 2004;34(3)137 141 Weekly Administration of Docetaxel in Patients with Hormonerefractory Prostate Cancer: a Pilot Study on Japanese Patients Takahiro Kojima, Toru Shimazui, Mizuki Onozawa,

More information

Vision of the Future: Capecitabine

Vision of the Future: Capecitabine Vision of the Future: Capecitabine CHRIS TWELVES Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom Key Words. Capecitabine

More information

Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy

Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS

More information

Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel

Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a

More information

Strontium 89 Combined with Gemcitabine in Androgen-Resistant Prostate Cancer: Results of a Phase I-II Study

Strontium 89 Combined with Gemcitabine in Androgen-Resistant Prostate Cancer: Results of a Phase I-II Study 54 The Open Prostate Cancer Journal, 2009, 2, 54-58 Open Access Strontium 89 Combined with Gemcitabine in Androgen-Resistant Prostate Cancer: Results of a Phase I-II Study Keizman Daniel, Maimon Natalie,

More information

Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T

Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater

More information

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR

More information

HOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):

HOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4): HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How

More information

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer The new england journal of medicine original article Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer Daniel P. Petrylak, M.D., Catherine M.

More information

ANTICANCER RESEARCH 26: (2006)

ANTICANCER RESEARCH 26: (2006) Gemcitabine plus Mitoxantrone and Prednisone in the Palliative Treatment of Hormone-resistant Prostate Cancer (HRPC): A Phase II Study (GOAM 01.01 Study) ANTONIA CRICCA 1, ANTONELLA MARINO 1, DANILA VALENTI

More information

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and

More information

Achieving Treatment Goals for Hormone-Refractory Prostate Cancer with Chemotherapy

Achieving Treatment Goals for Hormone-Refractory Prostate Cancer with Chemotherapy This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Achieving Treatment Goals for Hormone-Refractory Prostate Cancer

More information

reviews LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate therapy

reviews LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate therapy reviews therapy LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate Martin I. Resnick, MD, Lester Persky Professor and Chief, Department of Urology, Case Western Reserve University School

More information

Medical Treatments for Prostate Cancer

Medical Treatments for Prostate Cancer Medical Treatments for Prostate Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology, Princess Margaret Hospital and University of Toronto March 17, 2005 Brampton 1 A hypothetical

More information

Saad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT

Saad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to

More information

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical

More information

Definition Prostate cancer

Definition Prostate cancer Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation

More information

Management of castrate resistant disease: after first line hormone therapy fails

Management of castrate resistant disease: after first line hormone therapy fails Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The

More information

New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일

New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy

More information

3. Recognize the development of novel approaches to the treatment of HRPC.

3. Recognize the development of novel approaches to the treatment of HRPC. The Oncologist Mayo Clinic Hematology/Oncology Reviews State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer SUSAN GOODIN, KAMAKSHI V. RAO, ROBERT S. DIPAOLA The Cancer Institute

More information

Policy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015

Policy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015 Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT

More information

Philip Kantoff, MD Dana-Farber Cancer Institute

Philip Kantoff, MD Dana-Farber Cancer Institute CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests

More information

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease

More information

Evolution of Chemotherapy for. Cancer

Evolution of Chemotherapy for. Cancer Evolution of Chemotherapy for Hormone Refractory Prostate t Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology Princess Margaret Hospital and University of Toronto In 1985, two

More information

Incorporating New Agents into the Treatment Paradigm for Prostate Cancer

Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center

More information

Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma

Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature

More information

trial update clinical

trial update clinical trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.

More information

mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE

mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL

More information

Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer

Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,

More information

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650) NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY

More information

X, Y and Z of Prostate Cancer

X, Y and Z of Prostate Cancer X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios

More information

Prostate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone

Prostate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal

More information

FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER

FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER NEWS RELEASE Media Contact: Kimberly Ocampo (650) 467-0679 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Ajanta Horan (650) 467-1741 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF

More information

www.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)

More information

Rationale for Multimodality Therapy for High Risk Localized Prostate Cancer

Rationale for Multimodality Therapy for High Risk Localized Prostate Cancer Rationale for Multimodality Therapy for High Risk Localized Prostate Cancer 100 80 60 Cancer Death Rates for Men, US 1930-2002 Rate Per 100,000 Lung William K. Oh, M.D. 40 Stomach Colon & rectum Prostate

More information

A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer

A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer Original Article DOCETAXEL AND DEXAMETHASONE WITH ESTRAMUSTINE FOR HORMONE-REFRACTORY PROSTATE CANCER NELIUS et al. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine

More information

Please consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017

Please consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017 Page 1 of 2 Janssen Scientific Affairs, LLC 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560 800.526.7736 tel 609.730.3138 fax June 08, 2017 Joan McClure 275 Commerce Drive #300 Fort Washington,

More information

Clinical Policy: Thalidomide (Thalomid) Reference Number: PA.CP.PHAR.78 Effective Date: 09/11 Last Review Date: 04/18

Clinical Policy: Thalidomide (Thalomid) Reference Number: PA.CP.PHAR.78 Effective Date: 09/11 Last Review Date: 04/18 Clinical Policy: (Thalomid) Reference Number: PA.CP.PHAR.78 Effective Date: 09/11 Last Review Date: 04/18 Revision Log Description The intent of the criteria is to ensure that patients follow selection

More information

My name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.

My name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York. Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.

More information

Policy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043.

Policy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043. Cellular Immunotherapy forr Prostate Cancer Policy Number: 8.01.53 Origination: 11/2010 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for cellular immunotherapy for prostate

More information

Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego

Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego National Cancer Institute, Slovakia Translational Research Unit Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer Michal Mego 2 nd Department of Oncology, Faculty

More information

PI3K/mTOR Dual Inhibitor

PI3K/mTOR Dual Inhibitor PI3K/mTOR Dual Inhibitor LY3023414 Courtney KD, et al 1 Drug Discovery Platform: Cancer Cell Signaling A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the

More information

Dendritic Cell Based Cancer Vaccine Development

Dendritic Cell Based Cancer Vaccine Development Dendritic Cell Based Cancer Vaccine Development November 10, 2005 CVCWG Meeting Rob Hershberg, MD, PhD Chief Medical Officer 1 Meeting the challenges of developing cancer vaccines-- APC8015 (Provenge TM

More information

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? Clinical Medicine Insights: Oncology Consise Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management Options in Advanced Prostate Cancer: What is

More information

METRIC Study Key Eligibility Criteria

METRIC Study Key Eligibility Criteria The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).

More information

Adenocarcinoma of the prostate continues to be a major cause of

Adenocarcinoma of the prostate continues to be a major cause of 269 Phase II Trial of Paclitaxel, Estramustine, Etoposide, and Carboplatin in the Treatment of Patients with Hormone-Refractory Prostate Carcinoma David C. Smith, M.D. 1,2 Christopher H. Chay, M.D. 1 Rodney

More information

Advanced Prostate Cancer. November Jose W. Avitia, M.D

Advanced Prostate Cancer. November Jose W. Avitia, M.D Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000

More information

Elderly men with prostate cancer + ADT

Elderly men with prostate cancer + ADT Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Radium-223 chloride for the treatment of bone metastases in castrate resistant prostate cancer Draft scope Draft

More information

Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide

Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Review Article [1] April 01, 1997 By Clifford A. Hudis, MD [2] The recognition of paclitaxel's (Taxol's) activity

More information

Session VI A: Prostate Cancer Multidisciplinary Approach: a key to success

Session VI A: Prostate Cancer Multidisciplinary Approach: a key to success EORTC-GU Group Session VI A: Prostate Cancer Multidisciplinary Approach: a key to success Joaquim Bellmunt Geriatric Oncology: Cancer in Senior Adults. Madrid Melia Castilla, 8-10 November 2007. Multidisciplinary

More information

The legally binding text is the original French version

The legally binding text is the original French version The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed

More information

Prostate carcinoma remains the most common malignancy in the. Docetaxel and Ketoconazole in Advanced Hormone- Refractory Prostate Carcinoma

Prostate carcinoma remains the most common malignancy in the. Docetaxel and Ketoconazole in Advanced Hormone- Refractory Prostate Carcinoma 1855 Docetaxel and Ketoconazole in Advanced Hormone- Refractory Prostate Carcinoma A Phase I and Pharmacokinetic Study Peter J. Van Veldhuizen, M.D. 1 Gregory Reed, Ph.D. 2 Arvind Aggarwal, M.D. 1 Joaquina

More information

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled

More information

Name of Policy: Cellular Immunotherapy for Prostate Cancer

Name of Policy: Cellular Immunotherapy for Prostate Cancer Name of Policy: Cellular Immunotherapy for Prostate Cancer Policy #: 432 Latest Review Date: July 2014 Category: Medical Policy Grade: A Background/Definitions: As a general rule, benefits are payable

More information

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design: Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA

More information

Molecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin

Molecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin Molecular Imaging in the Development of Cancer Therapeutics Johannes Czernin Ahmanson Biological Imaging Division University of California Los Angeles Cancer Statistics Cancer Type 5-year Survival Rate

More information

SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia

SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract

More information

A PHASE 1 STUDY OF TRC105 (ANTI- ADVANCED SOLID TUMORS

A PHASE 1 STUDY OF TRC105 (ANTI- ADVANCED SOLID TUMORS ASCO 2011 Abstract Number: 3073 A PHASE 1 STUDY OF TRC105 (ANTI- CD105 ANTIBODY) IN PATIENTS WITH ADVANCED SOLID TUMORS J. W. Goldman, M. S. Gordon, H. Hurwitz, R. Pili, D. S. Mendelson, B. J. Adams, D.

More information

SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223

SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:

More information

Lipoplatin monotherapy for oncologists

Lipoplatin monotherapy for oncologists Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable

More information

Lecture 6: Antibiotic agents & Immunomodulators (immunomodulators act very differently)

Lecture 6: Antibiotic agents & Immunomodulators (immunomodulators act very differently) Lecture 6: Antibiotic agents & Immunomodulators (immunomodulators act very differently) 1. Macrolide antibiotics generally considered non-cell cycle specific but S-phase sensitive Dactinomycin (Cosmegen):

More information

It is a malignancy originating from breast tissue

It is a malignancy originating from breast tissue 59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast

More information

Early Chemotherapy for Metastatic Prostate Cancer

Early Chemotherapy for Metastatic Prostate Cancer Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,

More information

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right

More information

PROGNOSIS AND SURVIVAL

PROGNOSIS AND SURVIVAL CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link

More information

Mitchell H. Gold, M.D. President and CEO. 2 nd Annual African American Prostate Cancer Disparity Summit September 22, 2006

Mitchell H. Gold, M.D. President and CEO. 2 nd Annual African American Prostate Cancer Disparity Summit September 22, 2006 Mitchell H. Gold, M.D. President and CEO 2 nd Annual African American Prostate Cancer Disparity Summit September 22, 2006 1 Dendreon Corporation: A Biotechnology Company on the Verge of Changing the Way

More information

Docetaxel in Combination with Prednisolone for Hormone Refractory Prostate Cancer

Docetaxel in Combination with Prednisolone for Hormone Refractory Prostate Cancer Original Article Japanese Journal of Clinical Oncology Advance Access published October 22, 2009 Jpn J Clin Oncol 2009 doi:10.1093/jjco/hyp126 Docetaxel in Combination with Prednisolone for Hormone Refractory

More information

TRANSPARENCY COMMITTEE OPINION. 29 April 2009

TRANSPARENCY COMMITTEE OPINION. 29 April 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)

More information

A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer

A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer William D. Figg,* Sukyung Woo, Wenhui Zhu, Xiaohong Chen, A. Seun Ajiboye, Seth

More information

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr. BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:

More information

POMALYST (pomalidomide) for Previously Treated Multiple Myeloma

POMALYST (pomalidomide) for Previously Treated Multiple Myeloma POMALYST (pomalidomide) for Previously Treated What is POMALYST? POMALYST (pomalidomide) capsule is an oral immunomodulatory therapy (a thalidomide analogue) indicated for patients with multiple myeloma

More information

MOLECULAR AND CLINICAL ONCOLOGY 4: , 2016

MOLECULAR AND CLINICAL ONCOLOGY 4: , 2016 MOLECULAR AND CLINICAL ONCOLOGY 4: 839-844, 2016 Clinical outcomes of anti androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial

More information

Advances in Prostate Cancer Chemotherapy: A New Era Begins 1

Advances in Prostate Cancer Chemotherapy: A New Era Begins 1 Advances in Prostate Cancer Chemotherapy: A New Era Begins 1 Kenneth J. Pienta, MD 2 ; David C. Smith, MD Dr. Pienta is Professor of Medicine and Urology, American Cancer Society Clinical Research Professor,

More information

High Efficacy of Docetaxel with and without Androgen Deprivation and Estramustine in Preclinical Models of Advanced Prostate Cancer

High Efficacy of Docetaxel with and without Androgen Deprivation and Estramustine in Preclinical Models of Advanced Prostate Cancer High Efficacy of Docetaxel with and without Androgen Deprivation and Estramustine in Preclinical Models of Advanced Prostate Cancer KARIM FIZAZI 1, CHARLES R. SIKES 2, JERI KIM 2, JUN YANG 3, LUIS A. MARTINEZ

More information

Adverse side effects associated to metronomic chemotherapy

Adverse side effects associated to metronomic chemotherapy Adverse side effects associated to metronomic chemotherapy Elisabetta Munzone, MD Division of Medical Senology Istituto Europeo di Oncologia Milano, Italy LDM: the optimal biological dose Although there

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS

More information

Monitoring Patients Undergoing Cancer Therapy. By Timothy K. Egan

Monitoring Patients Undergoing Cancer Therapy. By Timothy K. Egan F E A T U R E By Timothy K. Egan Before placement in a computed tomography scanner, a patient is fitted with an immobilization device. Immobilization ensures that the same area of the patient is scanned

More information

A Phase II Trial of Estramustine and Etoposide in Hormone Refractory Prostate Cancer: A Southwest Oncology GroupTrial (SWOG 9407)

A Phase II Trial of Estramustine and Etoposide in Hormone Refractory Prostate Cancer: A Southwest Oncology GroupTrial (SWOG 9407) The Prostate 46:257^261 (2001) A Phase II Trial of Estramustine and Etoposide in Hormone Refractory Prostate Cancer: A Southwest Oncology GroupTrial (SWOG 9407) Kenneth J. Pienta, 1 * Emily I. Fisher,

More information

Initial Hormone Therapy

Initial Hormone Therapy Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA

More information

Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,

Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide, Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the

More information

Management of castration resistant prostate cancer after first line hormonal therapy fails

Management of castration resistant prostate cancer after first line hormonal therapy fails Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?

More information

METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /

METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin

More information

37 Novel Therapies for

37 Novel Therapies for 37 Novel Therapies for Multiple Myeloma Abstract: Current standard of management for newly diagnosed multiple myeloma are continuously evolving due to the advent of a number of novel agents with different

More information

Molecular Imaging and Cancer

Molecular Imaging and Cancer Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the U.S. Department of Health and Human Services, more than 512,000

More information

Summary... 2 GENITOURINARY TUMOURS - PROSTATE... 3

Summary... 2 GENITOURINARY TUMOURS - PROSTATE... 3 ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 GENITOURINARY TUMOURS - PROSTATE... 3 Custirsen provides no additional survival benefit to cabazitaxel/prednisone

More information

Management of castrate resistant disease: after first line hormone therapy fails

Management of castrate resistant disease: after first line hormone therapy fails Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support

More information

The Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer

The Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical

More information

ISPUB.COM. S Ravi-Kumar, S Lee, I Rabinowitz, C Verschraegen INTRODUCTION

ISPUB.COM. S Ravi-Kumar, S Lee, I Rabinowitz, C Verschraegen INTRODUCTION ISPUB.COM The Internet Journal of Oncology Volume 7 Number 2 Does Ethnicity Influence Response To Docetaxel Based- Chemotherapy For Patients With Castration Resistant Prostate Cancer? The New Mexico Perspective.

More information

Certified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018)

Certified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018) Certified Breast Care Nurse (CBCN ) Test Content Outline (Effective 2018) I. Coordination of Care - 26% A. Breast health, screening, early detection, risk assessment and reduction 1. Issues related to

More information

During the past several decades, endocrine manipulations

During the past several decades, endocrine manipulations chapter 110 Emmanuel S. Antonarakis, MD Michael A. Carducci, MD Mario A. Eisenberger, MD Treatment of Castration- Resistant Prostate Cancer Clinical Considerations Cytotoxic Chemotherapy Palliative Management

More information

Comparative Study of Toxicity of Weekly versus Three -Weekly Regimen of Paclitaxel in Locally Advanced Breast Cancer

Comparative Study of Toxicity of Weekly versus Three -Weekly Regimen of Paclitaxel in Locally Advanced Breast Cancer IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 79-85, p-issn: 79-86.Volume 5, Issue Ver. IX (December. 6), PP 9-98 www.iosrjournals.org Comparative Study of Toxicity of Weekly versus Three

More information

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION VOLUME 23 NUMBER 28 OCTOBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Predictors of Prostate Cancer Specific Mortality After Radical Prostatectomy or Radiation Therapy Ping Zhou,

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate

Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate ORIGINAL RESEARCH Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate Robert J. Amato and Joan Hernandez-McClain Genitourinary

More information